• LAST PRICE
    4.3700
  • TODAY'S CHANGE (%)
    Trending Up0.1000 (2.3419%)
  • Bid / Lots
    4.3000/ 19
  • Ask / Lots
    4.7800/ 2
  • Open / Previous Close
    4.2600 / 4.2700
  • Day Range
    Low 4.2000
    High 4.4884
  • 52 Week Range
    Low 3.9501
    High 1,130.4000
  • Volume
    25,409
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 4.27
TimeVolumeAVTX
09:32 ET32354.2414
09:35 ET7194.36
09:37 ET1024.22
09:53 ET5004.2459
10:00 ET7504.29
10:15 ET5004.36
10:26 ET2004.32
10:31 ET1144.3399
10:51 ET4004.2
11:02 ET1974.23
11:54 ET10004.3499
11:56 ET30004.29
11:57 ET21004.3384
11:59 ET1004.35
12:30 ET1494.3371
12:44 ET1504.2445
01:31 ET15004.295
01:33 ET1004.32
02:14 ET1004.33
02:34 ET3494.35
02:43 ET2004.31
02:56 ET11004.36
02:59 ET1004.43
03:01 ET4454.4383
03:03 ET12894.4884
03:06 ET2004.39
03:26 ET2524.391
03:28 ET5004.37
03:30 ET4504.35
03:33 ET11094.46
03:46 ET1004.469
03:51 ET1004.4796
04:00 ET1004.37
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAVTX
Avalo Therapeutics Inc
3.4M
0.0x
---
United StatesEMMA
Emmaus Life Sciences Inc
4.7M
-1.4x
---
United StatesRGDXQ
Response Genetics Inc
40.0
0.0x
---
United StatesVDRM
Viaderma Inc
8.8M
0.0x
---
United StatesSQZB
SQZ Biotechnologies Co
1.3M
0.0x
---
United StatesNBY
NovaBay Pharmaceuticals Inc
1.0M
0.0x
---
As of 2024-02-22

Company Information

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. It is focused on advancing a pipeline that emphasizes high value potential first-in-class biologics focused on dysregulated inflammation through the LIGHT-signaling network. Its pipeline includes AVTX-002, and AVTX-008. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, Crohn’s Disease, and COVID-19 acute respiratory distress syndromes. AVTX-008 is a fully human B and T lymphocyte attenuator (BTLA) agonist fusion protein that is being evaluated for several immune dysregulation disorders.

Contact Information

Headquarters
540 Gaither Rd Ste 400ROCKVILLE, MD, United States 20850-6713
Phone
410-522-8707
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Garry Neil
Chief Financial Officer
Christopher Sullivan
Lead Independent Director
Magnus Persson
Independent Director
June Almenoff
Independent Director
Mitchell Chan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.4M
Revenue (TTM)
$2.3M
Shares Outstanding
801.6K
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.68
EPS
$-620.74
Book Value
$-277.52
P/E Ratio
0.0x
Price/Sales (TTM)
1.5
Price/Cash Flow (TTM)
---
Operating Margin
-1,268.76%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.